Author: paroukatos

20 Aug

Posted at 10:32h in 2007 Guidelines by

1. INTRODUCTION AND PURPOSES 2. DEFINITION AND CLASSIFICATION OF HYPERTENSION 2.1 Systolic versus diastolic and pulse pressure 2.2 Classification of hypertension 2.3 Total cardiovascular risk 2.3.1 Concept 2.3.2 Assessment 2.3.3 Limitations 3. DIAGNOSTIC EVALUATION 3.1 Blood pressure measurement 3.1.1 Office or clinic blood pressure 3.1.2 Ambulatory blood pressure 3.1.3 Home blood pressure 3.1.4 Isolated office or white coat...

20 Aug

Posted at 10:31h in 2007 Guidelines by

For several years the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) decided not to produce their own guidelines on the diagnosis and treatment of hypertension but to endorse the guidelines on hypertension issued by the WorldHealth Organization (WHO) and International...

20 Aug

Posted at 10:31h in Υπέρταση Οδηγίες by

JNC 7 Individuals with SBP of 120-139 or DBP of 80-89 mmHg should be considered as prehypertensive and require health promoting lifestyle modifications to prevent CVD "Prehypertension" - Criticism   Progression to HT less frequent in several studies "Hypertension" has an ominous significance by the layman Anxiety over the term may create need for...

20 Aug

Posted at 10:30h in Υπέρταση Οδηγίες by

Norman M Kaplan, Lionel H Opie Hypertension remains the most common risk factor for cardiovascular morbidity and mortality. Its incidence is rising in both ageing and obese populations, but its control remains inadequate worldwide. We address several persisting controversies that may interfere with appropriate management of...

20 Aug

Posted at 10:30h in Νέα - Ανακοινώσεις by

6o Πανελλήνιο συνέδριο - Σύγχρονες απόψεις στην Κλινική Διαχείριση των Παραγόντων Καρδιαγγειακού Κινδύνου 31 Μαΐου- 2 Ιουνίου 2019 Ξενοδοχείο "Ionian Blue" Λευκάδα...

20 Aug

Posted at 10:29h in Μελέτες by

ΑΝΔΡΕΑΣ ΠΙΤΤΑΡΑΣ MD Ο Κιρκάδειος τύπος διακύμανσης της Αρτηριακής πίεσης Κλινικές και θεραπευτικές επιπτώσεις Blood pressure varies widely over 24 hours, and this may contribute to the fact that acute cardiovascular events peak in the morning hours. Reducing morning BP may prevent these occurrences, and so identifying...

20 Aug

Posted at 10:28h in Μελέτες by

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the...

20 Aug

Posted at 10:27h in Μελέτες by

STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP CCB than an RAS inhibitor/thiazide diuretic in hypertensive patients with metabolic syndrome. STAR: rationale Metabolic syndrome associated with increased risk of new-onset diabetes and cardiovascular disease. Antihypertensive therapy may be beneficial in reducing...

20 Aug

Posted at 10:26h in Μελέτες by

TROPHY - hypothesis The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension. TROPHY - objectives Primary: to determine whether treatment with...